ALT logo

Altimmune (ALT) EBITDA

Annual EBITDA

-$87.94 M
-$3.53 M-4.18%

December 31, 2023

Summary

Performance

1-Year Change

-4.18%

3-Year Change

-62.77%

5-Year Change

-96.63%

15-Year Change

-69.88%

ALT EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

20.92%
ALT annual EBITDA is higher than 20.92% of companies in Healthcare sector

High & Low

All-time High

$325.30 K
ALT annual EBITDA is currently <-9900.00% below its historical high of $325.30 thousand

3-Year Low

-$96.53 M

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2023
ALT previous annual earnings announcement was published on Dec 31, 2023

Next Annual Earnings Report Date

Mar 27, 2025
ALT next annual earnings announcement is scheduled for Mar 27, 2025

OtherALTprofitabilitymetrics:

Annual Revenue

$426.00 K
ALT annual revenue is $426.00 thousand

Annual Net Income

-$88.45 M
ALT annual net profit is -$88.45 million

Annual EBIT

-$88.41 M
ALT annual earnings before interest & taxes is -$88.41 million

Annual EPS

-$1.66
ALT annual earnings per share is -$1.66

Quarterly EBITDA

-$22.80 M
+$1.78 M+7.23%

September 30, 2024

Summary

Performance

3-Month Change

+7.23%

1-Year Change

+27.67%

3-Year Change

+31.3%

5-Year Change

-109.01%

ALT Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

20.76%
ALT quarterly EBITDA is higher than 20.76% of companies in Healthcare sector

High & Low

All-time High

$2.25 M
ALT quarterly EBITDA is currently -1114.28% below its historical high of $2.25 million

3-Year Low

-$31.52 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
ALT previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Mar 27, 2025
ALT next earnings announcement is scheduled for Mar 27, 2025

OtherALTprofitabilitymetrics:

Quarterly Revenue

$5000.00
ALT quarterly revenue is $5000.00

Quarterly Net Income

-$22.84 M
ALT quarterly net profit is -$22.84 million

Quarterly EBIT

-$22.84 M
ALT quarterly earnings before interest & taxes is -$22.84 million

Quarterly EPS

-$0.32
ALT quarterly earnings per share is -$0.32

TTM EBITDA

-$103.19 M
-$2.28 M-2.26%

September 30, 2024

Summary

Performance

3-Month Change

-2.26%

1-Year Change

-17.35%

3-Year Change

-24%

5-Year Change

-411.12%

ALT TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

17.29%
ALT TTM EBITDA is higher than 17.29% of companies in Healthcare sector

High & Low

All-time High

$903.10 K
ALT TTM EBITDA is currently <-9900.00% below its historical high of $903.10 thousand

3-Year Low

-$103.19 M
ALT TTM EBITDA is currently at its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
ALT previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Mar 27, 2025
ALT next earnings announcement is scheduled for Mar 27, 2025

OtherALTprofitabilitymetrics:

TTM Revenue

$52.00 K
ALT TTM revenue is $52.00 thousand

TTM Net Income

-$103.52 M
ALT TTM net profit is -$103.52 million

TTM EBIT

-$103.51 M
ALT TTM earnings before interest & taxes is -$103.51 million

TTM EPS

-$1.57
ALT TTM earnings per share is -$1.57

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

Annual EBITDA

-$87.94 M
ALT annual EBITDA is -$87.94 million

Annual Net Income

-$88.45 M
ALT annual net profit is -$88.45 million

Annual Interest Expense

$35.00 K
ALT annual interest expense is $35.00 thousand

Annual Income Tax

$0.00
ALT annual income tax is $0.00

Annual D&A

$477.00 K
ALT annual depreciation & amortization is $477.00 thousand

ALT EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-4.2%+27.7%-17.4%
3 y3 years-62.8%+31.3%-24.0%
5 y5 years-96.6%-109.0%-411.1%

ALT EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-4.2%+8.9%-43.1%+27.7%-32.6%at low
5 y5-year-335.6%+8.9%-466.3%+31.3%-411.1%at low
alltimeall time<-9999.0%+8.9%-1114.3%+31.3%<-9999.0%at low

Altimmune EBITDA History

DateAnnualQuarterlyTTM
Sep 2024
-
-$22.80 M(-7.2%)
-$103.19 M(+2.3%)
Jun 2024
-
-$24.58 M(+1.2%)
-$100.91 M(+9.4%)
Mar 2024
-
-$24.29 M(-23.0%)
-$92.27 M(+4.9%)
Dec 2023
-$87.94 M(+4.2%)
-$31.52 M(+53.6%)
-$87.94 M(+13.0%)
Sep 2023
-
-$20.52 M(+28.8%)
-$77.79 M(-3.9%)
Jun 2023
-
-$15.94 M(-20.1%)
-$80.92 M(-4.8%)
Mar 2023
-
-$19.95 M(-6.7%)
-$84.97 M(+0.8%)
Dec 2022
-$84.41 M(-12.6%)
-$21.38 M(-9.6%)
-$84.27 M(-2.8%)
Sep 2022
-
-$23.65 M(+18.3%)
-$86.72 M(-9.9%)
Jun 2022
-
-$19.99 M(+3.8%)
-$96.26 M(-4.7%)
Mar 2022
-
-$19.25 M(-19.2%)
-$101.00 M(+4.6%)
Dec 2021
-$96.53 M(+78.7%)
-$23.83 M(-28.2%)
-$96.53 M(+16.0%)
Sep 2021
-
-$33.19 M(+34.2%)
-$83.22 M(+22.0%)
Jun 2021
-
-$24.73 M(+67.3%)
-$68.21 M(+10.5%)
Mar 2021
-
-$14.78 M(+40.5%)
-$61.74 M(+14.3%)
Dec 2020
-$54.02 M(+167.6%)
-$10.52 M(-42.1%)
-$54.02 M(+13.7%)
Sep 2020
-
-$18.18 M(-0.5%)
-$47.53 M(+18.1%)
Jun 2020
-
-$18.27 M(+158.9%)
-$40.26 M(+59.1%)
Mar 2020
-
-$7.06 M(+75.3%)
-$25.30 M(+25.3%)
Dec 2019
-$20.19 M(-54.9%)
-$4.03 M(-63.1%)
-$20.19 M(-53.3%)
Sep 2019
-
-$10.91 M(+229.5%)
-$43.26 M(+22.6%)
Jun 2019
-
-$3.31 M(+70.4%)
-$35.28 M(-17.1%)
Mar 2019
-
-$1.94 M(-92.8%)
-$42.54 M(-4.9%)
Dec 2018
-$44.72 M(-13.6%)
-$27.10 M(+825.3%)
-$44.72 M(+51.5%)
Sep 2018
-
-$2.93 M(-72.3%)
-$29.52 M(-49.1%)
Jun 2018
-
-$10.57 M(+156.2%)
-$57.99 M(+12.8%)
Mar 2018
-
-$4.12 M(-65.3%)
-$51.39 M(-0.7%)
Dec 2017
-$51.76 M(+374.3%)
-$11.90 M(-62.1%)
-$51.76 M(+20.7%)
Sep 2017
-
-$31.40 M(+691.2%)
-$42.88 M(+164.0%)
Jun 2017
-
-$3.97 M(-11.7%)
-$16.24 M(+17.4%)
Mar 2017
-
-$4.49 M(+48.5%)
-$13.84 M(+31.0%)
Dec 2016
-$10.91 M(+1426.3%)
-$3.02 M(-36.4%)
-$10.56 M(+25.5%)
Sep 2016
-
-$4.76 M(+203.6%)
-$8.42 M(+73.1%)
Jun 2016
-
-$1.57 M(+28.8%)
-$4.87 M(-12.8%)
Mar 2016
-
-$1.22 M(+38.1%)
-$5.58 M(+98.1%)
Dec 2015
-$715.00 K
-$880.80 K(-26.7%)
-$2.82 M(-43.5%)
Sep 2015
-
-$1.20 M(-47.3%)
-$4.99 M(-40.0%)
Jun 2015
-
-$2.28 M(-247.5%)
-$8.30 M(+30.2%)
DateAnnualQuarterlyTTM
Mar 2015
-
$1.55 M(-150.7%)
-$6.38 M(-36.5%)
Dec 2014
-$10.04 M(-9.6%)
-$3.05 M(-32.5%)
-$10.04 M(-11.0%)
Sep 2014
-
-$4.52 M(+1180.3%)
-$11.28 M(+7.0%)
Jun 2014
-
-$353.00 K(-83.3%)
-$10.55 M(-6.5%)
Mar 2014
-
-$2.12 M(-50.6%)
-$11.28 M(+10.6%)
Dec 2013
-$11.11 M(+171.2%)
-$4.29 M(+13.5%)
-$10.20 M(+45.7%)
Sep 2013
-
-$3.78 M(+249.2%)
-$7.00 M(+117.1%)
Jun 2013
-
-$1.08 M(+4.4%)
-$3.22 M(+19.7%)
Mar 2013
-
-$1.04 M(-5.3%)
-$2.69 M(-34.2%)
Dec 2012
-$4.10 M(+24.8%)
-$1.10 M(>+9900.0%)
-$4.10 M(+92.8%)
Sep 2012
-
-$6900.00(-98.8%)
-$2.12 M(+4.8%)
Jun 2012
-
-$552.60 K(-77.4%)
-$2.03 M(-46.4%)
Mar 2012
-
-$2.44 M(-378.8%)
-$3.78 M(+15.2%)
Dec 2011
-$3.28 M(-85.9%)
$875.50 K(+863.1%)
-$3.28 M(-72.3%)
Sep 2011
-
$90.90 K(-103.9%)
-$11.86 M(-21.2%)
Jun 2011
-
-$2.31 M(+18.7%)
-$15.06 M(-16.5%)
Mar 2011
-
-$1.94 M(-74.8%)
-$18.04 M(-22.4%)
Dec 2010
-$23.26 M(-7.4%)
-$7.71 M(+148.1%)
-$23.26 M(+8.9%)
Sep 2010
-
-$3.11 M(-41.2%)
-$21.36 M(-16.3%)
Jun 2010
-
-$5.28 M(-26.2%)
-$25.53 M(-4.8%)
Mar 2010
-
-$7.16 M(+23.2%)
-$26.82 M(+7.4%)
Dec 2009
-$25.10 M(+37.2%)
-$5.81 M(-20.2%)
-$24.98 M(+5.1%)
Sep 2009
-
-$7.28 M(+10.8%)
-$23.77 M(+18.7%)
Jun 2009
-
-$6.57 M(+23.5%)
-$20.03 M(+6.0%)
Mar 2009
-
-$5.32 M(+15.7%)
-$18.90 M(+3.3%)
Dec 2008
-$18.30 M(+15.8%)
-$4.60 M(+29.8%)
-$18.29 M(-2.9%)
Sep 2008
-
-$3.54 M(-35.0%)
-$18.83 M(+0.6%)
Jun 2008
-
-$5.44 M(+15.6%)
-$18.72 M(+69.8%)
Mar 2008
-
-$4.71 M(-8.4%)
-$11.02 M(+23.6%)
Dec 2007
-$15.80 M(+12.4%)
-$5.14 M(+50.0%)
-$8.92 M(+3.4%)
Sep 2007
-
-$3.43 M(-252.4%)
-$8.63 M(+1.8%)
Jun 2007
-
$2.25 M(-186.4%)
-$8.48 M(-18.4%)
Mar 2007
-
-$2.60 M(-46.3%)
-$10.39 M(+37.6%)
Dec 2006
-$14.05 M(-4419.1%)
-$4.85 M(+48.0%)
-$7.55 M(+198.4%)
Sep 2006
-
-$3.28 M(-1069.4%)
-$2.53 M(-380.0%)
Jun 2006
-
$337.90 K(+42.3%)
$903.10 K(+59.8%)
Mar 2006
-
$237.40 K(+38.6%)
$565.20 K(+72.4%)
Dec 2005
$325.30 K
$171.30 K(+9.5%)
$327.80 K(+109.5%)
Sep 2005
-
$156.50 K
$156.50 K

FAQ

  • What is Altimmune annual EBITDA?
  • What is the all time high annual EBITDA for Altimmune?
  • What is Altimmune annual EBITDA year-on-year change?
  • What is Altimmune quarterly EBITDA?
  • What is the all time high quarterly EBITDA for Altimmune?
  • What is Altimmune quarterly EBITDA year-on-year change?
  • What is Altimmune TTM EBITDA?
  • What is the all time high TTM EBITDA for Altimmune?
  • What is Altimmune TTM EBITDA year-on-year change?

What is Altimmune annual EBITDA?

The current annual EBITDA of ALT is -$87.94 M

What is the all time high annual EBITDA for Altimmune?

Altimmune all-time high annual EBITDA is $325.30 K

What is Altimmune annual EBITDA year-on-year change?

Over the past year, ALT annual EBITDA has changed by -$3.53 M (-4.18%)

What is Altimmune quarterly EBITDA?

The current quarterly EBITDA of ALT is -$22.80 M

What is the all time high quarterly EBITDA for Altimmune?

Altimmune all-time high quarterly EBITDA is $2.25 M

What is Altimmune quarterly EBITDA year-on-year change?

Over the past year, ALT quarterly EBITDA has changed by +$8.72 M (+27.67%)

What is Altimmune TTM EBITDA?

The current TTM EBITDA of ALT is -$103.19 M

What is the all time high TTM EBITDA for Altimmune?

Altimmune all-time high TTM EBITDA is $903.10 K

What is Altimmune TTM EBITDA year-on-year change?

Over the past year, ALT TTM EBITDA has changed by -$15.26 M (-17.35%)